BMS Reports Results from the P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for Metastatic Colorectal Cancer (mCRC)
Shots:
- BMS highlights results from the P-III (CheckMate -8HW) study of Opdivo (240mg, followed by 480mg, Q4W) + Yervoy (1mg/kg, Q3W, 4 doses) vs Opdivo (240mg, Q2W, 6 doses, followed by 480mg, Q4W) as monotx. or CT (mFOLFOX-6/FOLFIRI with/without bevacizumab/cetuximab) for the 1L treatment of MSI-H/dMMR mCRC patients (n=830), at ASCO GI 2024
- The results reveal that the combination showed improved PFS of 79% at ~3mos., mPFS was not attained vs 5.9mos. in the CT arm. Consistent PFS benefit was seen in patients with KRAS or NRAS mutations & baseline liver, lung, or peritoneal metastases. OS is being evaluated
- The safety profile of the combination was consistent, grade 3/4 TRAEs were seen in 23% vs 48% and the grade TRAE-related discontinuation occurred in 17% vs 32% in the CT arm
Ref: BMS | Image: BMS
Related News:- Gilead and Compugen Sign an Exclusive License Agreement to Develop COM503, a Novel Pre-Clinical Immunotherapy Program
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
